Novocure Publishes 2018 Annual Report Featuring Company’s Vision, Mission and Values

April 15, 2019 11:30 UTC

Novocure’s mission and values support its overarching patient-forward vision to make a difference in cancer

ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today the publication of its 2018 Annual Report featuring its vision, mission and values, employee stories and videos, business highlights and selected financial information. In 2018, Novocure made a commitment to put into words its vision, mission and values as part of its corporate objective of investing in its people and culture.

The publication of the 2018 Annual Report marks the public debut of Novocure’s newly defined vision, mission and values. Novocure launched its vision, mission and values internally to its nearly 600 employees at the end of 2018.

“We as a company are very proud of our vision, mission and values that have been a part of who we are from day one,” said Novocure CEO Asaf Danziger. “We believe our values, the core traits that we share, will help us to achieve our mission of striving to extend survival in some of the most aggressive forms of cancer.”

To view the digital version of our 2018 Annual Report, please visit 2018.novocure.com.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized product is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory submission and approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 28, 2019, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

Contacts

Media and Investor Contact:
Ashley Cordova
acordova@novocure.com
212-767-7558

 

Source: Novocure

Back to news